Tyme Technologies Inc. (TYME)

[mcsharkey]

Jan 20-22, 2022 Moscone West • San Francisco, CA & Online #GI22
Abstracts and Posters for the 2022 Gastrointestinal Cancers Symposium are available for searching. Posters will be released at 8 AM ET on the first day of the symposium. Online posters are available for download on the ASCO Meeting Library beginning the same day, but the specific timing depends on uploading by individual presenters.


Little teaser available in a couple of AGENDA files

This excerpt found in the test handout accompanying the POSTER that's not available.

Conclusions:
This final analysis confirmed that SM-88 Regimen was well tolerated, with patients attaining an overall Disease Control Rate (DCR) of 27%.

Of note, for the small subset of patients treated in the second line, the mOS and mPFS were on par
with results achieved in other published randomized PhIII second-line trials for mPDAC.


Moreover, SM-88 Regimen exhibited far fewer Grade 3 and 4 AEs than other commonly used cytotoxic regimens in the second line. The 27% DCR, 8.1 mo mOS, and 3.8 mo mPFS in the second line, with minimal toxicity and preserved QOL, resulted in the active investigation of SM-88 Regimen in a large, ongoing second-line trial in mPDAC (NCT04229004).

Clinical trial information: NCT03512756. Research
Sponsor: TYME Inc.

Oral SM-88 plus MPS, an effective yet less toxic treatment option in second-line
advanced pancreatic cancer? Final phase II/III study results.

This link will get you a detailed file of all the projects being presented. Ours is on the 67th pdf page

..........................
Disease Control Rate (DCR) and Clinical Benefit Rate (CBR) are defined as the percentage of patients with advanced or metastatic cancer who have achieved complete response, partial response and stable disease to a therapeutic intervention in clinical trials of anticancer agents

mOS. Median OS. Medical ; 1. MOS. Median Overall Survival ·